Pfizer (PFE) is a leading drug manufacturers - general business based in the US. It opened the day at $30.15 after a previous close of $29.76. During the day the price has varied from a low of $30.01 to a high of $30.80. The latest price was $30.72 (25 minute delay). Pfizer is listed on the NYSE and employs 88,000 staff. All prices are listed in US Dollars.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Open | $30.15 |
|---|---|
| High | $30.80 |
| Low | $30.01 |
| Close | $30.72 |
| Previous close | $29.76 |
| Change | $0.96 |
| Change % | 3.2261% |
| Volume | 21,131,148 |
| 52-week range | $24.83 - $35.80 |
|---|---|
| 50-day moving average | $28.37 |
| 200-day moving average | $28.52 |
| Wall St. target price | $28.92 |
| PE ratio | N/A |
| Dividend yield | $1.65 (5.65%) |
| Earnings per share (TTM) | $-0.05 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $30.7201 from 2024-07-25
| 1 week (2024-07-19) | 2.50% |
|---|---|
| 1 month (2024-06-26) | 12.04% |
| 3 months (2024-04-26) | 20.95% |
| 6 months (2024-01-26) | 11.83% |
| 1 year (2023-07-26) | -17.44% |
|---|---|
| 2 years (2022-07-26) | -41.26% |
| 3 years (2021-07-26) | 41.4347 |
| 5 years (2019-07-26) | 37.4157 |
Valuing Pfizer stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pfizer's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Pfizer's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.256. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Pfizer's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Pfizer's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $9.6 billion.
The EBITDA is a measure of a Pfizer's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $54.9 billion |
|---|---|
| Operating margin TTM | 31.63% |
| Gross profit TTM | $66.2 billion |
| Return on assets TTM | 0.93% |
| Return on equity TTM | -0.26% |
| Profit margin | -0.56% |
| Book value | $16.28 |
| Market Capitalization | $168.3 billion |
TTM: trailing 12 months
Dividend payout ratio: 117.61% of net profits
Recently Pfizer has paid out, on average, around 117.61% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 5.65% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Pfizer shareholders could enjoy a 5.65% return on their shares, in the form of dividend payments. In Pfizer's case, that would currently equate to about $1.65 per share.
Pfizer's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Pfizer's most recent dividend payout was on 2 September 2024. The latest dividend was paid out to all shareholders who bought their shares by 25 July 2024 (the "ex-dividend date").
Pfizer's shares were split on a 1054:1000 basis on 16 November 2020. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1054 shares. This wouldn't directly have changed the overall worth of your Pfizer shares – just the quantity. However, indirectly, the new 5.1% lower share price could have impacted the market appetite for Pfizer shares which in turn could have impacted Pfizer's share price.
Over the last 12 months, Pfizer's shares have ranged in value from as little as $24.8256 up to $35.7995. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Pfizer's is 0.634. This would suggest that Pfizer's shares are less volatile than average (for this exchange).
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.